• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Avalon GloboCare to Present at the Jefferies 2022 Healthcare Conference

    5/25/22 9:00:00 AM ET
    $AVCO
    Building operators
    Real Estate
    Get the next $AVCO alert in real time by email

    FREEHOLD, N.J., May 25, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ:AVCO), a leading global developer of innovative cell-based technologies and therapeutics, announced today that David Jin, M.D., Ph.D., President and Chief Executive Officer, and Luisa Ingargiola, Chief Financial Officer, of Avalon GloboCare, will be presenting at the Jefferies 2022 Healthcare Conference which is being held on June 8–10, 2022 in New York City.

    Management is scheduled to present on Friday, June 10, 2022, at 12:45 PM ET. Management will also be available for one-on-one meetings with investors during the conference.

    About Avalon GloboCare Corp.



    Avalon GloboCare Corp. (NASDAQ:AVCO) is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.

    For the latest updates on Avalon GloboCare's developments, please follow our twitter at @avalongc_avco

    Forward-Looking Statements

    Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

    Contact Information:

    Avalon GloboCare Corp.

    4400 Route 9, Suite 3100

    Freehold, NJ 07728

    [email protected]

    Investor Relations:

    Crescendo Communications, LLC

    Tel: (212) 671-1020 Ext. 304

    [email protected]



    Primary Logo

    Get the next $AVCO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AVCO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AVCO
    SEC Filings

    See more
    • Avalon GloboCare Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Avalon GloboCare Corp. (0001630212) (Filer)

      11/22/23 4:49:04 PM ET
      $AVCO
      Building operators
      Real Estate
    • SEC Form 10-Q filed by Avalon GloboCare Corp.

      10-Q - Avalon GloboCare Corp. (0001630212) (Filer)

      11/14/23 4:30:53 PM ET
      $AVCO
      Building operators
      Real Estate
    • Avalon GloboCare Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - Avalon GloboCare Corp. (0001630212) (Filer)

      11/9/23 4:30:46 PM ET
      $AVCO
      Building operators
      Real Estate

    $AVCO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Tauzin W J

      4 - Avalon GloboCare Corp. (0001630212) (Issuer)

      3/9/23 11:12:55 AM ET
      $AVCO
      Building operators
      Real Estate
    • SEC Form 4 filed by Sanders Steven Andrew

      4 - Avalon GloboCare Corp. (0001630212) (Issuer)

      3/9/23 11:11:22 AM ET
      $AVCO
      Building operators
      Real Estate
    • SEC Form 4 filed by Stilley William B. Iii

      4 - Avalon GloboCare Corp. (0001630212) (Issuer)

      3/8/23 4:45:24 PM ET
      $AVCO
      Building operators
      Real Estate

    $AVCO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Avalon GloboCare Corp. (Amendment)

      SC 13D/A - Avalon GloboCare Corp. (0001630212) (Subject)

      1/24/24 8:35:42 PM ET
      $AVCO
      Building operators
      Real Estate

    $AVCO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avalon GloboCare Announces NASDAQ Ticker Symbol Change from "AVCO" to "ALBT"

      Company to Begin Trading under New Symbol "ALBT" on November 10, 2022 Symbol Change Better Reflects Avalon's New Focus on Laboratory Services and Biotherapeutics FREEHOLD, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:AVCO), a leading global developer of innovative cell-based technologies and therapeutics, today announced that its ticker symbol will change on the NASDAQ Stock Exchange from "AVCO" to "ALBT" at the open of market trading on Thursday, November 10, 2022. David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon, commented, "Yesterday we announced a transformative acquisition of Laboratory Services MSO, LLC,

      11/9/22 4:00:00 PM ET
      $AVCO
      Building operators
      Real Estate
    • Avalon GloboCare Signs Definitive Agreement for Transformational Acquisition of Leading Laboratory with 2021 Unaudited Revenue in Excess of $25 Million

      Company to acquire a majority interest in Laboratory Services MSO, LLC, a leading reference laboratory with 2021 unaudited revenue in excess of $25 million, net income in excess of $10 million and over 600,000 tests completed since inception Cash portion to be financed with a private placement of $15 million of Avalon preferred stock, convertible at a floor of $1.00 per share, with leak-out provisions, no warrants and a 9-month lock up Company to Begin Trading under New Symbol "ALBT" on November 10, 2022 FREEHOLD, N.J., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company")(NASDAQ:AVCO), a leading global developer of innovative cell-based technologies and

      11/8/22 9:10:00 AM ET
      $AVCO
      Building operators
      Real Estate
    • Avalon Globocare to Present at the LD Micro Main Event XV on October 26th

      Freehold, New Jersey--(Newsfile Corp. - October 19, 2022) - Avalon GloboCare Corp. (NASDAQ:AVCO), a leading global developer of innovative cell-based technologies and therapeutics, announced today that David Jin, M.D., Ph.D., President and Chief Executive Officer, and Luisa Ingargiola, Chief Financial Officer of Avalon GloboCare, will be presenting at the 15th annual LD Micro Main Event being held on October 25 - 27, 2022 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.Presentation details:Event:LD Micro Main Event XVDate:Wednesday, October 26th, 2022Time:4:00 PM PT/ 7:00 PM ET Register to watch the virtual presentation here.Management will be available for one-on-one meetings

      10/19/22 9:00:00 AM ET
      $AVCO
      Building operators
      Real Estate

    $AVCO
    Leadership Updates

    Live Leadership Updates

    See more
    • Avalon GloboCare Signs MOU to Form Strategic Partnership with Lu Daopei Hematology Institute to Develop Precision Companion Diagnostics for Cellular Therapy

      Goal of Partnership is to expand Avalon's R&D pipeline to include innovative companion diagnostics in association with the company's ongoing and future cellular immunotherapy clinical programs Appoints Dr. Hongxing Liu, a world-renowned expert in precision diagnostics for hematologic malignancies, to its Scientific and Clinical Advisory Board to further strengthen Avalon's companion diagnostics development capabilities FREEHOLD, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ:AVCO), a leading global developer of innovative cell-based technologies and therapeutics, announced today that the Company has signed a memorandum of understanding (MOU) with Lu Daopei Hematol

      5/18/22 9:00:00 AM ET
      $AVCO
      Building operators
      Real Estate
    • Siyata Mobile Appoints Peter Goldstein as Chairman and Adds Seasoned Public Company Executive Luisa Ingargiola to Board of Directors

      VANCOUVER, British Columbia, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Siyata Mobile Inc. (Nasdaq: SYTA, SYTAW) (“Siyata” or the “Company”), a leading global developer and provider of cellular communications solutions for enterprise customers, today announces the appointment of Peter Goldstein, currently a Siyata Board member, as the Chairman of its Board of Directors. In addition, Luisa Ingargiola, who has extensive experience on public company boards and in the capital markets, has been appointed to the Board of Directors effective as of the shareholders meeting on February 23, 2021. “Peter’s many years in working with emerging growth, publicly traded companies is paramount to our asking him to

      2/9/21 10:30:49 AM ET
      $SYTA
      $AVCO
      $SOLO
      $UAVS
      Telecommunications Equipment
      Telecommunications
      Building operators
      Real Estate